Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : H001
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : H001 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cardiovascular Diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 09, 2025
Lead Product(s) : H001
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Esomeprazole Magnesium
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nexium (Esomeprazole Magnesium) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Esophagitis, Peptic.
Product Name : Nexium
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 27, 2025
Lead Product(s) : Esomeprazole Magnesium
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LZM012
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate the Efficacy and Safety of LZM012
Details : LZM012 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Psoriasis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 01, 2023
Lead Product(s) : LZM012
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ilaprazole Sodium
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ilaprazole Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Stomach Ulcer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 03, 2023
Lead Product(s) : Ilaprazole Sodium
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zastaprazan
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Recipient : Onconic Therapeutics
Deal Size : $127.5 million
Deal Type : Acquisition
Livzon Acquires Rights to GERD Therapy from Onconic for $127.5 Million
Details : Zastaprazan is a P-CAB (potassium-competitive acid-blocking) candidate, a class of drugs that is replacing existing PPIs (proton pump inhibitors) for peptic ulcer disease, including GERD. Livzon will have rights to JP 1366 (zastaprazan) in China, Taiwan,...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $15.0 million
March 14, 2023
Lead Product(s) : Zastaprazan
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Recipient : Onconic Therapeutics
Deal Size : $127.5 million
Deal Type : Acquisition
Lead Product(s) : V-01
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : V-01 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 19, 2022
Lead Product(s) : V-01
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : V-01D-351
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : V-01D-351 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 17, 2022
Lead Product(s) : V-01D-351
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Recombinant SARS-CoV-2 Beta/Delta Variant Fusion Protein Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
The Immunogenicity and Safety of V-01-351/V-01D Bivalence Vaccine
Details : Recombinant SARS-CoV-2 Beta/Delta Variant Fusion Protein Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
March 10, 2022
Lead Product(s) : Recombinant SARS-CoV-2 Beta/Delta Variant Fusion Protein Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Recombinant SARS-CoV-2 Fusion Protein Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Recombinant SARS-CoV-2 Fusion Protein Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
February 15, 2022
Lead Product(s) : Recombinant SARS-CoV-2 Fusion Protein Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Recombinant SARS-CoV-2 Fusion Protein Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Recombinant SARS-CoV-2 Fusion Protein Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
February 14, 2022
Lead Product(s) : Recombinant SARS-CoV-2 Fusion Protein Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable